Mirna Mujacic is Vice President of Process and Analytical Development. Mirna brings 15-years of drug development experience in process development and analytics. Prior to joining GentiBio, Mirna contributed to the development of CAR-T cell therapies targeting blood cancers at Juno Therapeutics/Bristol Myers Squibb in process development and CMC team leadership roles. Before transitioning to cell therapy development, Mirna was a process development and technology lead on therapeutic monoclonal antibody programs at Amgen. Mirna holds a B.S. in Chemical Engineering and Ph.D. in Bioengineering from University of Washington.
Mirna Mujacic, PhD
VP, Process and Analytical Development
